Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Siolta Therapeutics Inc
Profile last edited on: 10/16/23      CAGE: 80CV3      UEI: L35PX15HHJQ7

Business Identifier: Biotech: developing therapeutic microbial consortia to prevent and treat inflammatory diseases
Year Founded
2017
First Award
2022
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

953 Indiana Street
San Francisco, CA 94107
   (415) 991-0947
   N/A
   www.sioltatherapeutics.com
Location: Single
Congr. District: 11
County: San Francisco

Public Profile

Structured around human microbiome therapeutics designed to prevent and treat inflammatory diseases, the mnagement of Siolta Therapeutics Inc are leveraging the deep knowledge of the principals in gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. The effort is to enable medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics whereby to prevent inflammatory processes

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$1
Phase II Dollars
$979,061
Total Awarded
$979,062

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,972,299
Project Title: Anaerobic Manufacturing and Molecular Analytical Process Optimization to Support Clinical Development of Live Biotherapeutic Products
0 1 NIH $300,000
Project Title: A Synergistic Multistrain Live Biotherapeutic Product for the Prevention and Treatment of Necrotizing Enterocolitis

Key People / Management

  Nikole E Kimes -- Founder & Chief Executive Officer

  Susan Lynch -- Founder and Board of Directors

  Richard S Shames -- Chief Medical Officer

  Ricardo Valladares -- Chief Scientific Officer

Company News

There are no news available.